John Rogers's CRL Position Overview
John Rogers (via Ariel Investments, LLC) currently holds 1.49 M shares of Charles River Laboratories International, Inc. (CRL) worth $233.14 M, representing 2.49% of the portfolio. First purchased in 2013-Q2, this long-term strategic position has been held for 50 quarters.
Based on 13F filings since 2013, John Rogers has maintained a long-term strategic position in CRL, representing a significant commitment to this investment thesis. Largest addition occurred in Q1 2017, adding 483,564 shares. Largest reduction occurred in Q1 2014, reducing 619,955 shares.
Analysis based on 13F filings available since 2013 Q2
John Rogers's Charles River Laboratories International (CRL) Holding Value Over Time
Track share changes against reported price movement
Quarterly Charles River Laboratories International (CRL) Trades by John Rogers
| Period | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2013 | +2.73 M | Add 0.00% | 2.73 M | $41.03 |
| Q3 2013 | +15,455 | Add 0.57% | 2.75 M | $46.26 |
| Q4 2013 | -120,688 | Reduce 4.39% | 2.63 M | $53.04 |
| Q1 2014 | -619,955 | Reduce 23.58% | 2.01 M | $60.34 |
| Q2 2014 | -58,605 | Reduce 2.92% | 1.95 M | $53.52 |
| Q3 2014 | +45,613 | Add 2.34% | 2 M | $59.74 |
| Q4 2014 | +7,785 | Add 0.39% | 2 M | $63.64 |
| Q1 2015 | -245,610 | Reduce 12.26% | 1.76 M | $79.29 |
| Q2 2015 | -78,795 | Reduce 4.48% | 1.68 M | $70.34 |
| Q3 2015 | -5,320 | Reduce 0.32% | 1.67 M | $63.52 |
| Q4 2015 | +68,560 | Add 4.09% | 1.74 M | $80.39 |
| Q1 2016 | -75,935 | Reduce 4.36% | 1.67 M | $75.94 |
| Q2 2016 | -202,825 | Reduce 12.17% | 1.46 M | $82.44 |
| Q3 2016 | -37,288 | Reduce 2.55% | 1.43 M | $83.34 |
| Q4 2016 | +150,014 | Add 10.51% | 1.58 M | $76.19 |
| Q1 2017 | +483,564 | Add 30.67% | 2.06 M | $89.95 |
| Q2 2017 | -110,053 | Reduce 5.34% | 1.95 M | $101.15 |
| Q3 2017 | -270,301 | Reduce 13.86% | 1.68 M | $108.02 |
| Q4 2017 | -326,871 | Reduce 19.46% | 1.35 M | $109.45 |
| Q1 2018 | +8,082 | Add 0.60% | 1.36 M | $106.74 |
| Q2 2018 | -43,691 | Reduce 3.21% | 1.32 M | $112.26 |
| Q3 2018 | -63,620 | Reduce 4.83% | 1.25 M | $134.54 |
| Q4 2018 | -265,795 | Reduce 21.20% | 988,171 | $113.18 |
| Q1 2019 | -141,729 | Reduce 14.34% | 846,442 | $145.25 |
| Q2 2019 | -30,935 | Reduce 3.65% | 815,507 | $141.90 |
| Q3 2019 | +26,090 | Add 3.20% | 841,597 | $132.37 |
| Q4 2019 | +8,497 | Add 1.01% | 850,094 | $152.76 |
| Q1 2020 | -164,511 | Reduce 19.35% | 685,583 | $126.21 |
| Q2 2020 | -60,977 | Reduce 8.89% | 624,606 | $174.35 |
| Q3 2020 | -134,264 | Reduce 21.50% | 490,342 | $226.45 |
| Q4 2020 | -77,476 | Reduce 15.80% | 412,866 | $249.86 |
| Q1 2021 | -1,793 | Reduce 0.43% | 411,073 | $289.83 |
| Q2 2021 | -189,974 | Reduce 46.21% | 221,099 | $369.92 |
| Q3 2021 | -37,894 | Reduce 17.14% | 183,205 | $412.67 |
| Q4 2021 | -3,558 | Reduce 1.94% | 179,647 | $376.78 |
| Q1 2022 | +30,148 | Add 16.78% | 209,795 | $283.97 |
| Q2 2022 | +379,844 | Add 181.05% | 589,639 | $213.97 |
| Q3 2022 | +60,859 | Add 10.32% | 650,498 | $196.80 |
| Q4 2022 | -12,736 | Reduce 1.96% | 637,762 | $217.90 |
| Q1 2023 | +45,292 | Add 7.10% | 683,054 | $201.82 |
| Q2 2023 | +364,786 | Add 53.41% | 1.05 M | $210.25 |
| Q3 2023 | +18,760 | Add 1.79% | 1.07 M | $195.98 |
| Q4 2023 | -15,902 | Reduce 1.49% | 1.05 M | $236.40 |
| Q1 2024 | -117,891 | Reduce 11.22% | 932,807 | $270.95 |
| Q2 2024 | -26,670 | Reduce 2.86% | 906,137 | $206.58 |
| Q3 2024 | -8,450 | Reduce 0.93% | 897,687 | $196.97 |
| Q4 2024 | +169,640 | Add 18.90% | 1.07 M | $184.60 |
| Q1 2025 | +33,449 | Add 3.13% | 1.1 M | $150.52 |
| Q2 2025 | +314,572 | Add 28.58% | 1.42 M | $151.73 |
| Q3 2025 | +74,750 | Add 5.28% | 1.49 M | $156.46 |
John Rogers's Charles River Laboratories International Investment FAQs
John Rogers first purchased Charles River Laboratories International, Inc. (CRL) in Q2 2013, acquiring 2,734,450 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
John Rogers has held Charles River Laboratories International, Inc. (CRL) for 50 quarters since Q2 2013. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
John Rogers's largest addition to Charles River Laboratories International, Inc. (CRL) was in Q2 2013, adding 2,734,450 shares worth $112.19 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
According to the latest 13F filing for Q3 2025, John Rogers's firm, Ariel Investments, LLC, owns 1,490,098 shares of Charles River Laboratories International, Inc. (CRL), valued at approximately $233.14 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
As of the Q3 2025 filing, Charles River Laboratories International, Inc. (CRL) represents approximately 2.49% of John Rogers's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
John Rogers's peak holding in Charles River Laboratories International, Inc. (CRL) was 2,749,905 shares, as reported at the end of Q3 2013. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.